<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01628549</url>
  </required_header>
  <id_info>
    <org_study_id>PR-10411</org_study_id>
    <nct_id>NCT01628549</nct_id>
  </id_info>
  <brief_title>Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of P005672 in Treatment of Facial Acne Vulgaris</brief_title>
  <official_title>A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Different Doses of P005672 Compared to Placebo in the Treatment of Facial Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Warner Chilcott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Warner Chilcott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and effectiveness of 3 strengths of P005672 compared to placebo for
      the treatment of moderate to severe facial acne.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammatory Lesion Count, Absolute Change from Baseline</measure>
    <time_frame>Week 12</time_frame>
    <description>Sum of inflammatory lesions (nodules [palpable solid lesion &gt; 0.5 cm with depth, not necessarily elevated], papule [ solid, elevated lesion &lt;0.5 cm] &amp; pustules [elevated lesion containing pus &lt; 0.5 cm]) found on the forehead, left &amp; right cheeks, nose and chin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dichotomized IGA (Investigator's Global Assessment) Score, Change from Baseline</measure>
    <time_frame>Week 12</time_frame>
    <description>IGA Scale 0/clear-clear skin no inflammatory or noninflammatory lesions, 1/almost clear-rare noninflammatory lesions, no more than 1 small inflammatory lesion, 2/mild-&gt;than 1 with some noninflammatory lesions, no more than a few inflammatory lesions [papules/pustules only, no nodular lesions], 3/moderate-&gt;2, up to many noninflammatory lesions &amp; may have some inflammatory lesions,no more than 1 small nodular lesion, 4/severe- &gt;3, up to many noninflammatory &amp; noninflammatory lesions, but no more than a few nodular lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Lesion Count, Percent Change from Baseline</measure>
    <time_frame>Week 12</time_frame>
    <description>Sum of inflammatory lesions on the forehead, left &amp; right cheeks, nose and chin. Calculated as Baseline value minus post-Baseline value divided by Baseline value, expressed as a percentage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Noninflammatory Lesion Count, Percent Change from Baseline</measure>
    <time_frame>Week 12</time_frame>
    <description>Sum of non-inflammatory lesions (open [blackhead] &amp; closed [whitehead] comedones) found on the forehead, left &amp; right cheeks, nose and chin. Calculated as Baseline value minus post-Baseline value divided by Baseline value, expressed as a percentage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Noninflammatory Lesion Count, Absolute Change from Baseline</measure>
    <time_frame>Week 12</time_frame>
    <description>Sum of non-inflammatory lesions on the forehead, left &amp; right cheeks, nose and chin. Calculated as Baseline value minus post-Baseline value.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">285</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>50 mg P005672</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 50 mg capsule P005672 and 1 matching placebo capsule, 1 capsule from each bottle taken orally each day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg P005672</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 50 mg capsules, 1 capsule from each bottle taken orally each day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg P005672</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 100 mg capsules, 1 capsule from each bottle taken orally each day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 placebo capsules matching WC3035, 1 capsule from each bottle taken orally each day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>50 mg P005672</intervention_name>
    <description>50 mg P0005672 taken daily for 84 days at doses achieving 0.75 or 1.5 mg/kg daily treatment</description>
    <arm_group_label>50 mg P005672</arm_group_label>
    <arm_group_label>100 mg P005672</arm_group_label>
    <other_name>WC3035</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo capsule matching 50 mg or 100 mg capsules of P0005672 taken daily for 84 days</description>
    <arm_group_label>50 mg P005672</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Inactive</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100 mg P005672</intervention_name>
    <description>100 mg P0005672 taken daily for 84 days a dose achieving 3.0 mg/kg daily treatment</description>
    <arm_group_label>200 mg P005672</arm_group_label>
    <other_name>WC3035</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female, 12-45 years of age with body weight between 52 and 88 kg

          -  diagnosis of acne vulgaris with:

          -  20 to 50 inflammatory lesions (papules, pustules, and nodules)

          -  30 to 100 noninflammatory lesions (open &amp; closed comedones)

          -  no more than 2 nodules on the face

          -  Investigator's Global Assessment (IGA) score of moderate (3) to severe (4)

        Exclusion Criteria:

          -  dermatological condition of face or facial hair that could interfere with clinical
             evaluations

          -  prolonged QTcF(&gt;450msec) on Baseline ECG

          -  pseudomembranous colitis or antibiotic-associated colitis

          -  hepatitis, liver damage or renal impairment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herman Ellman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Warner Chilcott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Gainsville</city>
        <state>Florida</state>
        <zip>32605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Granger</city>
        <state>Indiana</state>
        <zip>46530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>44532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Sandy</city>
        <state>Utah</state>
        <zip>84070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2012</study_first_submitted>
  <study_first_submitted_qc>June 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2012</study_first_posted>
  <disposition_first_submitted>December 11, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>December 11, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 13, 2014</disposition_first_posted>
  <last_update_submitted>April 9, 2015</last_update_submitted>
  <last_update_submitted_qc>April 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acne</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

